# Pfizer (PFIZER) — Stock analysis

> Faxioms all-in-one stock review. Canonical page: https://faxioms.com/stocks/pfizer

## Current market snapshot

- Exchange: NSE
- Country: India
- Price: ₹3,857
- Change: +0.00%
- As of: 2026-11-06
- 1D return: +0.00%
- 5D return: +4.59%
- 1M return: +2.85%
- Latest complete quarter: fy27_q2

## Faxioms Analysis

_As of 2026-11-06_

### Technical Outlook

As of 2026-11-06, Pfizer (₹3,857.0) exhibits a conflicting technical structure: short-term momentum is positive while the broader trend remains bearish. The stock has surged +6.8% over the past 10 days, driven by extreme anomalies including a volume-backed move on 2026-11-03 and an upward gap on 2026-11-05. This recent strength places the price above its 20-day EMA and SMA, with a daily ADX of 29.41 indicating established short-term trend strength. However, the price remains below key longer-term averages (50-day and 200-day SMAs) and the Supertrend across daily, weekly, and monthly timeframes. The monthly ADX is weak at 12.62, suggesting the primary downtrend lacks conviction but persists. The stock trades near the lower end of its 252-day range (+15.3%) and carries a significant current drawdown of -34.5%. Immediate resistance lies at ₹3,865.53 (pivot), with support at ₹3,826.37.

- Short-term bullish divergence: Price is above 20-day EMAs/SMA with strong daily ADX (29.41), supported by recent extreme volume and gap-up anomalies.
- Long-term bearish context: Price remains below 50/200-day SMAs and Supertrend on daily, weekly, and monthly charts; monthly trend is weak (ADX 12.62).
- Key levels to monitor: Resistance at ₹3,865.53 (0.22% above); Support at ₹3,826.37 (0.79% below). A break above ₹3,865.53 would be required to confirm further upside.
- Risk profile: High volatility (annualized vol +25.9%, ATR 2.87%) and deep historical drawdown (-34.5% current, -38.7% maximum) persist.

- Inside Bar
- Doji
- Bearish Engulfing Reversal
- Evening Star
- Hammer

### News Context

Pfizer India reported its Q2 results on November 3, 2026, revealing a significant surge in profitability driven by non-operational factors. The company posted a net profit of ₹313 crore, marking a 65.6% year-on-year increase. This jump was primarily attributable to a one-time gain of ₹132 crore. On the top line, revenue grew 13.2% to ₹727 crore, while EBITDA expanded 14.4% to ₹262 crore. Despite the earnings growth, the EBITDA margin remained flat at 36%, indicating that operational efficiency did not improve proportionally with revenue. Following these disclosures, Pfizer’s shares on the BSE rose 3.37%. In broader market context, Pfizer was listed among key global entities reporting earnings during the week of November 2–6, alongside peers such as Apple and Amgen.

- Q2 Net Profit: ₹313 crore (up 65.6% YoY), heavily influenced by a ₹132 crore one-time gain.
- Revenue Growth: Top-line sales increased 13.2% to ₹727 crore, while EBITDA margin held steady at 36%.
- Market Reaction: BSE share price gained 3.37% following the Q2 result announcement on November 3.
- Global Context: Pfizer was identified as a major earnings reporter for the week of November 2–6, alongside other large-cap technology and healthcare firms.

- [Pfizer Q2 Results: Stock up 5% after net profit jumps 66% on ₹132 crore one-time gain](https://www.cnbctv18.com/market/stocks/pfizer-share-price-q2-results-stock-up-5-after-net-profit-jumps-66-on-rs-132-crore-one-time-gain-20025996.htm)
- [Dow Jones, Nasdaq futures rebound after brutal sell-off; Here's why this week is important](https://www.cnbctv18.com/market/dow-jones-snp-500-nasdaq-rebound-sell-off-morgan-stanley-buy-the-dip-key-triggers-this-week-midterms-results-jobs-20024426.htm)

### Official Filings

Pfizer Limited’s Board approved unaudited financial results for the quarter and half-year ended September 30, 2026, reporting revenue from operations of ₹726.86 crore and a net profit of ₹313.25 crore. The profit figure includes a significant one-time exceptional item of ₹132.06 crore, which is a lump-sum payment received from Pfizer Inc. USA following the discontinuation of Minipress XL marketing and distribution effective September 7, 2026. This product withdrawal stems from a manufacturing decision by Pfizer Inc. USA.

Statutory auditor B S R & Co. LLP issued an unmodified limited review report, confirming no material misstatements or compliance issues were identified in these results. Separately, the company disclosed receipt of an Income Tax Transfer Pricing order dated September 25, 2026, levying a penalty of Rs. 1,26,34,050 for alleged non-furnishing of granular information during the Assessment Year 2023-24 audit. Pfizer Limited considers this order not maintainable and is preparing to appeal, asserting that the penalty will have no material impact on its financial position or operations.

- Q2 FY2027 Net Profit: ₹313.25 crore, including a ₹132.06 crore exceptional lump-sum payment from Pfizer Inc. USA linked to the discontinuation of Minipress XL.
- Revenue from Operations: ₹726.86 crore for the quarter ended September 30, 2026; statutory auditor issued an unmodified limited review report.
- Tax Penalty: Rs. 1,26,34,050 levied by the Deputy/Additional Commissioner of Income Tax (Transfer Pricing) for AY 2023-24; company intends to appeal and expects no material financial impact.

- [Pfizer Limited has submitted to the Exchange, the financial results for the period ended September 30, 2026. |SUBJECT: Outcome of Board Meeting](https://nsearchives.nseindia.com/corporate/PFIZER_03112026141109_SEintimation_FRQ22027.pdf)
- [Integrated Filing- Financials|Original|](https://nsearchives.nseindia.com/corporate/xbrl/INTEGRATED_FILING_INDAS_1752078_03112026064602_WEB.xml)
- [Financial Results |Meeting Date: 03-Nov-2026](https://nsearchives.nseindia.com/corporate/PFIZER_26102026183304_Stock_Exchange_Intimation_Board_Meeting_-_03112026.pdf)
- [Pfizer Limited has informed the Exchange about Board Meeting to be held on 03-Nov-2026 to inter-alia consider and approve the Unaudited Financial results of the Company for the Half Yearly ended September 2026 . |SUBJECT: Board Meeting Intimation](https://nsearchives.nseindia.com/corporate/xbrl/PRIOR_INTIMATION_245_WebXMLFile_20261026_183608647.xml)
- [Board Meeting Intimation |Meeting Date: 03-Nov-2026](https://nsearchives.nseindia.com/corporate/xbrl/PRIOR_INTIMATION_245_WebXMLFile_20261026_183608647.xml)
- [Pfizer Limited has informed the Exchange about Certificate under SEBI (Depositories and Participants) Regulations, 2018 |SUBJECT: Certificate under SEBI (Depositories and Participants) Regulations, 2018](https://nsearchives.nseindia.com/corporate/PFIZER_09102026165731_SEintimation.pdf)
- [Pfizer Limited has informed the Exchange about Copy of Newspaper Publication |SUBJECT: Copy of Newspaper Publication](https://nsearchives.nseindia.com/corporate/PFIZER_02102026183158_SEintimation_Relodgment.pdf)
- [Pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, we hereby inform that the Company has, on September 28, 2026, received an Order dated September 25, 2026, issued by the Deputy / Additional Commissioner of Income tax Transfer Pricing, levying a penalty of Rs. 1,26,34,050/- based on the Transfer Pricing audit conducted for the Assessment Year 2023-24. |SUBJECT: Action(s) initiated or orders passed](https://nsearchives.nseindia.com/corporate/PFIZER_29092026130308_Stock_Exchange_Intimation_-_Regulation_30.pdf)
- [Pfizer Limited has informed the Exchange about Closure of Trading Window |SUBJECT: Trading Window-XBRL](https://nsearchives.nseindia.com/corporate/xbrl/CLOSURE_TRADING_WINDOW_245_WebXMLFile_20260929_165641364.xml)
- [Pfizer Limited has informed the Exchange about Action(s) taken or orders passed (sub-para 20) |SUBJECT: Actions initiated/taken or orders passed-XBRL](https://nsearchives.nseindia.com/corporate/xbrl/AIATOP_245_WebXMLFile_20260929_165837926.xml)

### Fundamentals

Pfizer’s operating trajectory has strengthened significantly in the most recent reported periods, marked by robust top-line growth and improving profitability. For Q2 FY2026-27 (ended September 2026), revenue from operations rose sequentially to ₹727 crore, while net profit more than doubled to ₹313 crore compared to ₹204 crore in Q1. This acceleration is supported by a sharp rise in other income to ₹179 crore in the quarter, contributing to a Profit Before Tax of ₹423 crore. On an annualized basis, the company posted TTM sales of ₹2,654 crore with a 12% compounded sales growth rate over the trailing twelve months, alongside a strong Return on Equity of 18%.

Financial health remains solid, with ROCE improving to 24% in Mar 2026 and working capital efficiency notably enhancing as Working Capital Days dropped sharply to 9 days. However, cash flow dynamics show a divergence: while Cash from Operating Activity surged to ₹968 crore in Mar 2026, Cash from Financing Activity turned deeply negative at -₹798 crore, likely reflecting debt repayment or shareholder returns. Concurrently, cash reserves declined from ₹205 crore to ₹92.8 crore by September 2026. Ownership structure is stable, with promoters holding 63.92% and DIIs increasing their stake slightly to 17.52%, while FIIs reduced theirs to 1.63%.

The key checkpoint for the next period is monitoring whether the surge in 'Other Income' sustains net profit margins and if the heavy financing outflows continue without straining liquidity, given the drop in cash balances.

- Q2 FY2026-27 Net Profit jumped to ₹313 crore (from ₹204 crore in Q1) driven by higher Other Income (₹179 crore) and sequential Revenue growth to ₹727 crore.
- TTM metrics show strong momentum: 12% Compounded Sales Growth, 13% Compounded Profit Growth, and a high Return on Equity of 18%.
- Balance sheet efficiency improved markedly in Mar 2026, with ROCE rising to 24% and Working Capital Days collapsing to 9 days.
- Cash position tightened: Cash from Financing Activity was -₹798 crore in Mar 2026, and Cash & Equivalents fell to ₹92.8 crore by Sep 2026.

### Bull Case

Pfizer India demonstrated operational resilience in Q2 FY2026, with revenue rising 13.2% year-on-year to ₹727 crore and EBITDA expanding 14.4% to ₹262 crore. The company maintained a stable EBITDA margin of 36%, indicating effective cost management despite top-line growth. Net profit surged 65.6% to ₹313 crore, primarily driven by a one-time gain of ₹132 crore, which supported a positive market reaction with the BSE share price rising 3.37%. While technical indicators across daily, weekly, and monthly timeframes remain bearish, with the stock trading near recent lows and showing negative slope trends, the fundamental earnings beat provides a conditional basis for constructive interpretation. This upside case is contingent on the sustainability of organic revenue growth and margin stability, rather than the non-recurring financial event that inflated profits.

- Q2 revenue grew 13.2% YoY to ₹727 crore, while EBITDA expanded 14.4% to ₹262 crore, maintaining a flat 36% margin.
- Net profit increased 65.6% YoY to ₹313 crore, supported by a one-time gain of ₹132 crore, triggering a 3.37% rise in share price.
- Technical structure remains bearish across all timeframes, with the stock down -23.9% over the past year and currently in a significant drawdown.

- [Pfizer Q2 Results: Stock up 5% after net profit jumps 66% on ₹132 crore one-time gain](https://www.cnbctv18.com/market/stocks/pfizer-share-price-q2-results-stock-up-5-after-net-profit-jumps-66-on-rs-132-crore-one-time-gain-20025996.htm)
- [Dow Jones, Nasdaq futures rebound after brutal sell-off; Here's why this week is important](https://www.cnbctv18.com/market/dow-jones-snp-500-nasdaq-rebound-sell-off-morgan-stanley-buy-the-dip-key-triggers-this-week-midterms-results-jobs-20024426.htm)
- [Pfizer Limited has submitted to the Exchange, the financial results for the period ended September 30, 2026. |SUBJECT: Outcome of Board Meeting](https://nsearchives.nseindia.com/corporate/PFIZER_03112026141109_SEintimation_FRQ22027.pdf)
- [Integrated Filing- Financials|Original|](https://nsearchives.nseindia.com/corporate/xbrl/INTEGRATED_FILING_INDAS_1752078_03112026064602_WEB.xml)
- [Financial Results |Meeting Date: 03-Nov-2026](https://nsearchives.nseindia.com/corporate/PFIZER_26102026183304_Stock_Exchange_Intimation_Board_Meeting_-_03112026.pdf)
- [Pfizer Limited has informed the Exchange about Board Meeting to be held on 03-Nov-2026 to inter-alia consider and approve the Unaudited Financial results of the Company for the Half Yearly ended September 2026 . |SUBJECT: Board Meeting Intimation](https://nsearchives.nseindia.com/corporate/xbrl/PRIOR_INTIMATION_245_WebXMLFile_20261026_183608647.xml)
- [Board Meeting Intimation |Meeting Date: 03-Nov-2026](https://nsearchives.nseindia.com/corporate/xbrl/PRIOR_INTIMATION_245_WebXMLFile_20261026_183608647.xml)
- [Pfizer Limited has informed the Exchange about Certificate under SEBI (Depositories and Participants) Regulations, 2018 |SUBJECT: Certificate under SEBI (Depositories and Participants) Regulations, 2018](https://nsearchives.nseindia.com/corporate/PFIZER_09102026165731_SEintimation.pdf)
- [Pfizer Limited has informed the Exchange about Copy of Newspaper Publication |SUBJECT: Copy of Newspaper Publication](https://nsearchives.nseindia.com/corporate/PFIZER_02102026183158_SEintimation_Relodgment.pdf)
- [Pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, we hereby inform that the Company has, on September 28, 2026, received an Order dated September 25, 2026, issued by the Deputy / Additional Commissioner of Income tax Transfer Pricing, levying a penalty of Rs. 1,26,34,050/- based on the Transfer Pricing audit conducted for the Assessment Year 2023-24. |SUBJECT: Action(s) initiated or orders passed](https://nsearchives.nseindia.com/corporate/PFIZER_29092026130308_Stock_Exchange_Intimation_-_Regulation_30.pdf)

### Bear Case

Pfizer’s recent performance on the NSE reveals a divergence between reported profitability and underlying operational momentum, alongside significant technical deterioration. While Q2 net profit rose 65.6% year-on-year to ₹313 crore, this surge was primarily driven by a one-time gain of ₹132 crore; without this item, organic growth appears muted. Revenue grew modestly at 13.2% to ₹727 crore, and EBITDA margin remained flat at 36%, indicating limited pricing power or cost efficiency gains despite top-line expansion.

Technically, the stock is under sustained pressure. The daily Supertrend is bearish, with the 20-day EMA slope negative (-0.42) and the 50-day SMA slope sharply declining (-108.97). Momentum indicators show selling dominance, with the Minus DI (24.05) exceeding the Plus DI (21.99). The stock has suffered a severe drawdown, currently down -34.5% from its peak, with a maximum historical drawdown of -38.7%. Year-to-date returns are deeply negative at -21.5%, and the one-year return stands at -23.9%. Volatility remains elevated at an annualized 25.9%, suggesting continued uncertainty. Immediate resistance sits tightly at ₹3,865.53, just 0.22% above the current close of ₹3,857.0, while support levels at ₹3,826.37 and ₹3,795.83 offer limited cushion against further downside.

- One-time gains drove profit: Q2 net profit jumped 65.6% to ₹313 crore, but ₹132 crore was a non-recurring item, masking slower organic revenue growth of 13.2% to ₹727 crore.
- Sustained technical breakdown: Daily and weekly Supertrends are bearish; the 50-day SMA slope is sharply negative (-108.97), and Minus DI (24.05) dominates Plus DI (21.99).
- Severe equity drawdown: The stock is down -34.5% from its high, with YTD returns at -21.5% and a one-year return of -23.9%, reflecting prolonged investor pessimism.
- Tight resistance ceiling: Current price (₹3,857.0) faces immediate resistance at ₹3,865.53 (0.22% away), limiting upside potential in the near term.

- [Pfizer Q2 Results: Stock up 5% after net profit jumps 66% on ₹132 crore one-time gain](https://www.cnbctv18.com/market/stocks/pfizer-share-price-q2-results-stock-up-5-after-net-profit-jumps-66-on-rs-132-crore-one-time-gain-20025996.htm)
- [Dow Jones, Nasdaq futures rebound after brutal sell-off; Here's why this week is important](https://www.cnbctv18.com/market/dow-jones-snp-500-nasdaq-rebound-sell-off-morgan-stanley-buy-the-dip-key-triggers-this-week-midterms-results-jobs-20024426.htm)
- [Pfizer Limited has submitted to the Exchange, the financial results for the period ended September 30, 2026. |SUBJECT: Outcome of Board Meeting](https://nsearchives.nseindia.com/corporate/PFIZER_03112026141109_SEintimation_FRQ22027.pdf)
- [Integrated Filing- Financials|Original|](https://nsearchives.nseindia.com/corporate/xbrl/INTEGRATED_FILING_INDAS_1752078_03112026064602_WEB.xml)
- [Financial Results |Meeting Date: 03-Nov-2026](https://nsearchives.nseindia.com/corporate/PFIZER_26102026183304_Stock_Exchange_Intimation_Board_Meeting_-_03112026.pdf)
- [Pfizer Limited has informed the Exchange about Board Meeting to be held on 03-Nov-2026 to inter-alia consider and approve the Unaudited Financial results of the Company for the Half Yearly ended September 2026 . |SUBJECT: Board Meeting Intimation](https://nsearchives.nseindia.com/corporate/xbrl/PRIOR_INTIMATION_245_WebXMLFile_20261026_183608647.xml)
- [Board Meeting Intimation |Meeting Date: 03-Nov-2026](https://nsearchives.nseindia.com/corporate/xbrl/PRIOR_INTIMATION_245_WebXMLFile_20261026_183608647.xml)
- [Pfizer Limited has informed the Exchange about Certificate under SEBI (Depositories and Participants) Regulations, 2018 |SUBJECT: Certificate under SEBI (Depositories and Participants) Regulations, 2018](https://nsearchives.nseindia.com/corporate/PFIZER_09102026165731_SEintimation.pdf)
- [Pfizer Limited has informed the Exchange about Copy of Newspaper Publication |SUBJECT: Copy of Newspaper Publication](https://nsearchives.nseindia.com/corporate/PFIZER_02102026183158_SEintimation_Relodgment.pdf)
- [Pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, we hereby inform that the Company has, on September 28, 2026, received an Order dated September 25, 2026, issued by the Deputy / Additional Commissioner of Income tax Transfer Pricing, levying a penalty of Rs. 1,26,34,050/- based on the Transfer Pricing audit conducted for the Assessment Year 2023-24. |SUBJECT: Action(s) initiated or orders passed](https://nsearchives.nseindia.com/corporate/PFIZER_29092026130308_Stock_Exchange_Intimation_-_Regulation_30.pdf)

### FAQs

**What drove Pfizer's Q2 net profit jump, and is it sustainable?**

Pfizer India reported a 65.6% year-on-year increase in Q2 net profit to ₹313.25 crore. This surge was primarily driven by a one-time exceptional item of ₹132.06 crore received from Pfizer Inc. USA following the discontinuation of Minipress XL marketing. Excluding this gain, underlying revenue grew 13.2% to ₹726.86 crore, with EBITDA margin remaining flat at 36%. The one-time nature of the payment means future profits may not reflect similar percentage jumps.

**How has the stock performed technically since the results announcement?**

As of November 6, 2026, Pfizer shares closed at ₹3,857.00, up approximately 3.37% on the day results were approved (November 3). Despite the positive earnings reaction, technical indicators show a bearish trend across daily, weekly, and monthly timeframes. The stock is trading below its 20-day and 50-day moving averages, with an ADX of 29.41 suggesting moderate trend strength in the downward direction. Year-to-date returns remain negative at -21.5%.

**What are the key support and resistance levels for near-term trading?**

Immediate resistance sits at ₹3,865.53 (pivot) and ₹3,896.07 (recent high), while support is found at ₹3,826.37 and ₹3,795.83. The stock recently traded between a low of ₹3,797.20 and a high of ₹3,881.90. A break above ₹3,896 could signal short-term momentum shift, whereas a decline below ₹3,795 may expose further downside toward ₹3,756.67. Current drawdown stands at -34.5% from peak levels.

- [Pfizer Q2 Results: Stock up 5% after net profit jumps 66% on ₹132 crore one-time gain](https://www.cnbctv18.com/market/stocks/pfizer-share-price-q2-results-stock-up-5-after-net-profit-jumps-66-on-rs-132-crore-one-time-gain-20025996.htm)
- [Dow Jones, Nasdaq futures rebound after brutal sell-off; Here's why this week is important](https://www.cnbctv18.com/market/dow-jones-snp-500-nasdaq-rebound-sell-off-morgan-stanley-buy-the-dip-key-triggers-this-week-midterms-results-jobs-20024426.htm)
- [Pfizer Limited has submitted to the Exchange, the financial results for the period ended September 30, 2026. |SUBJECT: Outcome of Board Meeting](https://nsearchives.nseindia.com/corporate/PFIZER_03112026141109_SEintimation_FRQ22027.pdf)
- [Integrated Filing- Financials|Original|](https://nsearchives.nseindia.com/corporate/xbrl/INTEGRATED_FILING_INDAS_1752078_03112026064602_WEB.xml)
- [Financial Results |Meeting Date: 03-Nov-2026](https://nsearchives.nseindia.com/corporate/PFIZER_26102026183304_Stock_Exchange_Intimation_Board_Meeting_-_03112026.pdf)
- [Pfizer Limited has informed the Exchange about Board Meeting to be held on 03-Nov-2026 to inter-alia consider and approve the Unaudited Financial results of the Company for the Half Yearly ended September 2026 . |SUBJECT: Board Meeting Intimation](https://nsearchives.nseindia.com/corporate/xbrl/PRIOR_INTIMATION_245_WebXMLFile_20261026_183608647.xml)
- [Board Meeting Intimation |Meeting Date: 03-Nov-2026](https://nsearchives.nseindia.com/corporate/xbrl/PRIOR_INTIMATION_245_WebXMLFile_20261026_183608647.xml)
- [Pfizer Limited has informed the Exchange about Certificate under SEBI (Depositories and Participants) Regulations, 2018 |SUBJECT: Certificate under SEBI (Depositories and Participants) Regulations, 2018](https://nsearchives.nseindia.com/corporate/PFIZER_09102026165731_SEintimation.pdf)
- [Pfizer Limited has informed the Exchange about Copy of Newspaper Publication |SUBJECT: Copy of Newspaper Publication](https://nsearchives.nseindia.com/corporate/PFIZER_02102026183158_SEintimation_Relodgment.pdf)
- [Pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, we hereby inform that the Company has, on September 28, 2026, received an Order dated September 25, 2026, issued by the Deputy / Additional Commissioner of Income tax Transfer Pricing, levying a penalty of Rs. 1,26,34,050/- based on the Transfer Pricing audit conducted for the Assessment Year 2023-24. |SUBJECT: Action(s) initiated or orders passed](https://nsearchives.nseindia.com/corporate/PFIZER_29092026130308_Stock_Exchange_Intimation_-_Regulation_30.pdf)
## Technical analytics

- As of: 2026-11-06
- Daily trend: Weak Uptrend
- Weekly trend: Weak Downtrend
- Pivot point: ₹3,865.53
- Risk regime: Higher Price Risk

### Support levels
- 3792.1
- 3716
- 3601.3

### Resistance levels
- 4201.049999999999
- 4356.3
- 4527.896875

### Return and range metrics

| Metric | Value |
| --- | --- |
| return_1 | +0.00% |
| return_10 | +6.77% |
| return_1m | +0.12% |
| return_1y | -23.89% |
| return_20 | +2.85% |
| return_3m | -21.29% |
| return_5 | +4.59% |
| return_6m | -19.36% |
| return_since_start | -27.33% |
| return_ytd | -21.54% |

### Risk and volatility metrics

| Metric | Value |
| --- | --- |
| state | high_risk |
| label | Higher price risk |
| summary | Recent drawdown or price variability is materially high and may lead to larger short-term outcomes. |
| maximum_drawdown | -38.66% |
| annualized_volatility | +25.86% |

## Quarterly financials

- Latest complete quarter: fy27_q2

# Pfizer Limited Q2 FY2026-27: Revenue up 13% year on year

Pfizer Limited’s revenue from operations rose 13.2% year on year to ₹726.86 crore in Q2 FY2026-27, while profit before exceptional items and tax increased 13.9% to ₹290.77 crore. Reported profit before tax (PBT) was ₹422.83 crore, including a ₹132.06 crore exceptional item; profit after tax (PAT) rose 65.7% year on year to ₹313.25 crore.

## Revenue and expenses

Total income was ₹774.19 crore, up 10.9% from ₹698.01 crore in Q1 FY2026-27 and 13.2% from ₹684.19 crore in Q2 FY2025-26. Revenue from operations increased 11.3% quarter on quarter and 13.2% year on year.

Expenses rose 14.7% quarter on quarter to ₹483.42 crore, faster than revenue from operations. Other expenses declined 7.7% to ₹76.96 crore. Reported expense lines included ₹206.28 crore for purchases of stock in trade, ₹56.51 crore for materials consumed, ₹91.43 crore in employee benefits and ₹34.48 crore from changes in inventories.

## Profitability and exceptional item

Profit before exceptional items and tax was ₹290.77 crore, up 5.1% from Q1 FY2026-27 and 13.9% from Q2 FY2025-26. The ₹132.06 crore exceptional item was described as a lump-sum amount for discontinuance of Minipress and recovery of incidental expenses. Including the item, PBT rose 52.8% quarter on quarter to ₹422.83 crore and 65.6% year on year.

Tax expense was ₹109.58 crore, compared with ₹72.21 crore in Q1 FY2026-27. PAT reached ₹313.25 crore, up 53.2% sequentially and 65.7% year on year from ₹189.02 crore. Basic earnings per share was ₹68.47, versus ₹44.69 in Q1 and ₹41.32 in Q2 FY2025-26; trailing twelve-month EPS was ₹187.85. Finance costs increased to ₹3.35 crore from ₹1.46 crore in Q1.

## Cash flow and balance sheet

Operating cash flow was ₹358.99 crore for the quarter. Investing activities used ₹2.80 crore, and reported free cash flow was ₹356.19 crore. Financing activities recorded an outflow of ₹366.03 crore.

At 30 September 2026, cash and cash equivalents stood at ₹92.82 crore, down from ₹102.66 crore at 31 March 2026. Bank balances other than cash and cash equivalents were ₹3,077.06 crore, compared with ₹3,008.10 crore at 31 March. Current financial assets totalled ₹3,550.35 crore.

Total assets were ₹5,292.98 crore, up from ₹4,921.88 crore at 31 March 2026. Equity attributable to owners of the parent rose to ₹4,385.41 crore from ₹4,202.90 crore. Property, plant and equipment increased to ₹267.47 crore from ₹136.13 crore, while capital work in progress was ₹31.48 crore.

## Results and filing

The board approved the unaudited results for the quarter ended 30 September 2026 at its meeting on 3 November 2026. The quarter’s reported PBT includes the ₹132.06 crore exceptional item; pre-exceptional profit before tax provides a separate view of the quarter’s profit performance.

## Key Takeaway

Revenue and pre-exceptional profit both grew year on year, while the exceptional item materially boosted reported PBT and PAT. Operating cash flow was strong, alongside a sizeable financing outflow and a decline in cash and cash equivalents from the 31 March 2026 balance.

### Ratios

## Shareholding pattern

- Quarter: FY2027-Q1
- As of: 2026-06-30
- Promoter holding: +63.92%
- FII holding: +1.65%
- DII holding: +17.80%
- Mutual fund holding: +12.68%
- Retail holding: +11.58%
- Promoter pledged: +0.00%

### Major reported shareholders

- PFIZER EAST INDIA B V — +39.75% (Other)
- WYETH LLC — +12.28% (Other)
- NIPPON LIFE INDIA TRUSTEE LTD — +4.17%
- LIFE INSURANCE CORPORATION OF INDIA — +3.74%
- WYETH HOLDINGS CORPORATION — +3.56% (Other)
- ICICI PRUDENTIAL FUND — +3.31%
- WARNER-LAMBERT COMPANY LLC — +2.60% (Other)
- QUANT MUTUAL FUND — +2.22%
- Atul Limited — +2.10%
- PARKE, DAVIS & COMPANY LLC — +2.09% (Other)

## Official filings

- 2026-11-03 — Generic Announcement: Pfizer Limited — [Official attachment](https://nsearchives.nseindia.com/corporate/PFIZER_03112026141109_SEintimation_FRQ22027.pdf)
- 2026-11-03 — Financial Results Filing: Pfizer Limited — [Official attachment](https://nsearchives.nseindia.com/corporate/xbrl/INTEGRATED_FILING_INDAS_1752078_03112026064602_WEB.xml)
- 2026-10-26 — Board Meeting Notice: Pfizer Limited — [Official attachment](https://nsearchives.nseindia.com/corporate/PFIZER_26102026183304_Stock_Exchange_Intimation_Board_Meeting_-_03112026.pdf)
- 2026-10-26 — Generic Announcement: Pfizer Limited — [Official attachment](https://nsearchives.nseindia.com/corporate/xbrl/PRIOR_INTIMATION_245_WebXMLFile_20261026_183608647.xml)
- 2026-10-26 — Board Meeting Notice: Pfizer Limited — [Official attachment](https://nsearchives.nseindia.com/corporate/xbrl/PRIOR_INTIMATION_245_WebXMLFile_20261026_183608647.xml)
- 2026-10-09 — Generic Announcement: Pfizer Limited — [Official attachment](https://nsearchives.nseindia.com/corporate/PFIZER_09102026165731_SEintimation.pdf)
- 2026-10-02 — Generic Announcement: Pfizer Limited — [Official attachment](https://nsearchives.nseindia.com/corporate/PFIZER_02102026183158_SEintimation_Relodgment.pdf)
- 2026-09-29 — Generic Announcement: Pfizer Limited — [Official attachment](https://nsearchives.nseindia.com/corporate/PFIZER_29092026130308_Stock_Exchange_Intimation_-_Regulation_30.pdf)
- 2026-09-29 — Generic Announcement: Pfizer Limited — [Official attachment](https://nsearchives.nseindia.com/corporate/xbrl/CLOSURE_TRADING_WINDOW_245_WebXMLFile_20260929_165641364.xml)
- 2026-09-29 — Generic Announcement: Pfizer Limited — [Official attachment](https://nsearchives.nseindia.com/corporate/xbrl/AIATOP_245_WebXMLFile_20260929_165837926.xml)
- 2026-09-29 — Generic Announcement: Pfizer Limited — [Official attachment](https://nsearchives.nseindia.com/corporate/PFIZER_29092026164138_Stock-Exchange_Intimation_Closure_of_Trading_Window_30092026.pdf)
- 2026-09-29 — Generic Announcement: Pfizer Limited — [Official attachment](https://nsearchives.nseindia.com/corporate/xbrl/CLOSURE_TRADING_WINDOW_245_WebXMLFile_20260929_164310463.xml)
- 2026-09-29 — Generic Announcement: Pfizer Limited — [Official attachment](https://nsearchives.nseindia.com/corporate/xbrl/AIATOP_245_WebXMLFile_20260929_164534612.xml)
- 2026-09-18 — Generic Announcement: Pfizer Limited — [Official attachment](https://nsearchives.nseindia.com/corporate/PFIZER_18092026163850_Stock_Exchange_Intimation_-_Change_in_SMP-SG.pdf)
- 2026-09-18 — Generic Announcement: Pfizer Limited — [Official attachment](https://nsearchives.nseindia.com/corporate/xbrl/CIM_245_WebXMLFile_20260918_165232733.xml)
- 2026-09-18 — Management Change: Pfizer Limited — [Official attachment](https://nsearchives.nseindia.com/corporate/PFIZER_ROID_98580_KMP_Doc.zip)
- 2026-09-18 — Generic Announcement: Pfizer Limited — [Official attachment](https://nsearchives.nseindia.com/corporate/xbrl/CIM_245_WebXMLFile_20260918_165450542.xml)
- 2026-09-18 — Management Change: Pfizer Limited — [Official attachment](https://nsearchives.nseindia.com/corporate/PFIZER_ROID_98582_KMP_Doc.zip)
- 2026-09-07 — Generic Announcement: Pfizer Limited — [Official attachment](https://nsearchives.nseindia.com/corporate/PFIZER_07092026112248_Stock_Exchange_Intimation_-_Outcome_of_the_Board_Meeting_07092026.pdf)
- 2026-08-04 — Generic Announcement: Pfizer Limited is publishing a notice regarding a special window for re-lodgement of transfer and dematerialisation of physical securities. This window, open from February 5, 2026, to February 4, 2027, is for securities purchased or sold before April 1, 2019, or where transfer requests were previously rejected due to documentation issues. The process requires submitting original physical share certificates and executed transfer deeds to the Registrar and Share Transfer Agent, MUFG Intime India Private Limited. — [Official attachment](https://nsearchives.nseindia.com/corporate/PFIZER_04082026165042_Stock_Exchange_Intimation_Re_lodgement_of_trading_window.pdf)
- 2026-07-29 — Generic Announcement: Pfizer Limited's 75th Annual General Meeting was held on July 28, 2026, where all resolutions were passed by the members. The resolutions included adopting the financial statements for the year ended March 31, 2026, declaring a final dividend of Rs. 75 per equity share, re-appointing a retiring director, and ratifying the remuneration of cost accountants for the financial year ending March 31, 2027. — [Official attachment](https://nsearchives.nseindia.com/corporate/PFIZER_29072026185750_Pfizer_Limited-Evoting_and_Scrutinizer_Report_75th_AGM_2026.pdf)
- 2026-07-28 — Generic Announcement: Pfizer Limited's Board of Directors approved the unaudited financial results for the quarter ended June 30, 2026, on July 28, 2026. The company reported total income of ₹698.01 crore and a net profit of ₹204.47 crore for the quarter. The results were subject to a limited review by statutory auditors B S R & Co. LLP, with no modifications noted. — [Official attachment](https://nsearchives.nseindia.com/corporate/PFIZER_28072026140140_Stock_Exchange_Intimation_-Outcome_of_the_Board_Meeting_28072026_final.pdf)
- 2026-07-28 — Generic Announcement: Pfizer Limited held its 75th Annual General Meeting on July 28, 2026, from 3:00 p.m. to 5:17 p.m. IST via video conferencing. The meeting included a tribute to the late former Chairman, R.A. Shah, a presentation on the company's performance and financial highlights for the year ended March 31, 2026, and discussions on ordinary and special business items. Key agenda items included the adoption of audited financial statements, declaration of a dividend of Rs. 75 per equity share, re-appointment of director P. Rengan, and ratification of remuneration for cost accountants. Results of the e-voting were to be declared within two working days. — [Official attachment](https://nsearchives.nseindia.com/corporate/PFIZER_28072026190613_Stock_Exchange_Intimation_-AGM_Proceedings__Covering_letter_28072026.pdf)
- 2026-07-27 — Generic Announcement: Mr. Amit Agarwal has resigned as Executive Director – Finance & Chief Financial Officer of Pfizer Limited, effective October 8, 2026, to pursue an opportunity outside the company. He will also cease to be a Director on the Board and a member of several committees effective the same date. — [Official attachment](https://nsearchives.nseindia.com/corporate/PFIZER_27072026164241_Stock_Exchange_Intimation_-_Resignation_of_Amit_Agarwal.pdf)
- 2026-07-27 — Official Filing: Pfizer Limited reported the resignation of Amit Agarwal from his position as Executive Director and Chief Financial Officer. The effective date for these changes is October 8, 2026. This disclosure pertains to a change in management for the listed entity.

## News and market events

- 2026-11-03 — CNBC-TV18: **Pfizer Q2 Results: Stock up 5% after net profit jumps 66% on ₹132 crore one-time gain** — Pfizer India reported a 65.6% year-on-year increase in Q2 net profit to ₹313 crore, driven by a one-time gain of ₹132 crore, while revenue rose 13.2% to ₹727 crore. EBITDA grew 14.4% to ₹262 crore with the margin remaining flat at 36%, leading to a 3.37% rise in the company's BSE share price. — [Source](https://www.cnbctv18.com/market/stocks/pfizer-share-price-q2-results-stock-up-5-after-net-profit-jumps-66-on-rs-132-crore-one-time-gain-20025996.htm)
- 2026-11-02 — CNBC-TV18: **Dow Jones, Nasdaq futures rebound after brutal sell-off; Here's why this week is important** — Apple, Palantir, AMD, Amgen, Qualcomm, ARM Holdings, Uber, and Pfizer are among the important companies reporting earnings results on Monday and Wednesday, with Apple reporting after Monday's market close, while Berkshire Hathaway will report its results on Friday. — [Source](https://www.cnbctv18.com/market/dow-jones-snp-500-nasdaq-rebound-sell-off-morgan-stanley-buy-the-dip-key-triggers-this-week-midterms-results-jobs-20024426.htm)
- 2026-10-28 — BUSINESSTODAY: **Pfizer India’s Meenakshi Nevatia on making new therapies more accessible** — Returning Pfizer’s India business to growth while bringing more of its global medicines to Indian patients has been a priority for Meenakshi Nevatia since she took charge as Managing Director in April 2023. — [Source](https://www.businesstoday.in/magazine/profile/story/pfizer-indias-meenakshi-nevatia-on-making-new-therapies-more-accessible-564271-2026-10-28)
- 2026-10-01 — Economic Times: **Where Does China Fit in Your Company’s Innovation Strategy? - The Economic Times** — For decades, multinationals treated China primarily as either a vast growth market or a rising competitive threat. But as growth slows, competition intensifies, and operating conditions become more difficult, many firms are rethinking China’s role. Increasingly, they are using the country not just as a destination market but as a platform for accelerating innovation—leveraging its fast-moving regulatory environment, tightly integrated R&D and manufacturing ecosystems, and deep engineering talent... — [Source](https://economictimes.indiatimes.com/hbr/strategy-growth-markets/where-does-china-fit-in-your-companys-innovation-strategy/articleshow/134532609.cms)
- 2026-09-29 — Mint: **Mint Explainer | Can the government make life-saving drugs cheaper? | Today News** — A Kerala high court order opens a legal route for the government to make expensive drugs available to patients on a non-commercial basis. — [Source](https://www.livemint.com/news/mint-explainer-can-the-government-make-lifesaving-drugs-cheaper-11790672713691.html)
- 2026-09-23 — Economic Times: **Pfizer India speaks up after Karnataka FDA crackdown, says patient safety is top priority** — Pfizer India has stated that patient safety and product quality are their top priorities following FDA actions. The Karnataka FDA canceled 16 drug licenses and suspended eight others due to counterfeit drugs. A raid uncovered an illegal operation repacking low-cost medicines as branded drugs, particularly Pfizer products. Pfizer has removed affected batches from the market and is cooperating with authorities in the investigation. — [Source](https://economictimes.indiatimes.com/industry/healthcare/biotech/healthcare/pfizer-india-speaks-up-after-karnataka-fda-crackdown-says-patient-safety-is-top-priority/articleshow/134426291.cms)
- 2026-09-23 — The Hindu: **Patient safety top priority, working with authorities on counterfeit medicine probe: Pfizer India** — Pfizer India prioritizes patient safety amid Karnataka FDA's crackdown on counterfeit drugs, canceling licenses of 16 retailers and wholesalers. — [Source](https://www.thehindubusinessline.com/companies/patient-safety-top-priority-working-with-authorities-on-counterfeit-medicine-probe-pfizer-india/article71498247.ece)
- 2026-09-23 — CNBC-TV18: **Karnataka fake drug case: Pfizer issues statement after FDA revokes licenses of 16 pharmacies** — Karnataka FDA revoked 16 pharmacy licenses, suspended 8, and the Pfizer C&F Distribution Centre license amid a counterfeit drug probe. Officials seized fake meds worth ₹5.05 crore from a Bidadi farmho — [Source](https://www.cnbctv18.com/business/karnataka-fake-drug-case-pfizer-issues-statement-after-fda-revokes-licenses-of-16-pharmacies-19996251.htm)
- 2026-09-23 — The Hindu: **Stock Market Today Highlights, Sept 23: Nifty closes at 23,446, gains 118 points, Sensex ends at 74,828 on stronger domestic growth momentum** — Sensex Today, Nifty 50 | Stock Market Highlights - Find here all the highlights related to Sensex, Nifty, BSE, NSE, share prices and Indian stock markets for 23 September 2026 — [Source](https://www.thehindubusinessline.com/markets/sensex-nifty50-today-stock-market-highlights-23rd-september-2026/article71495500.ece)
- 2026-09-22 — BUSINESSTODAY: **Here’s why ChrysCapital expects 20-25% of the latest $2.2-billion fund to go to pharma, healthcare** — Here’s why ChrysCapital expects 20-25% of the latest $2.2-billion fund to go to pharma, healthcare — [Source](https://www.businesstoday.in/industry/pharma/story/heres-why-chryscapital-expects-20-25-of-the-latest-2-2-billion-fund-to-go-to-pharma-healthcare-557090-2026-09-22)
- 2026-09-22 — Mint: **Pharmaceutical companies push Trump administration to protect China deals | Mint** — A surge in U.S.-China transactions is drawing scrutiny in Washington, where some lawmakers are pushing to slow the pace of investment. — [Source](https://www.livemint.com/global/pharmaceutical-companies-push-trump-administration-to-protect-china-deals-11790056491416.html)
- 2026-09-21 — FREEPRESSJOURNAL.IN: **Karnataka Spurious Drug Racket: Government Halts Business With Pfizer, Cancels Licences Of 16 Firms Over Counterfeit Medicine Manufacturing** — Karnataka has stopped business with Pfizer and suspended transactions with 14 stockists amid a spurious drug racket in Bengaluru. Licences of 16 firms were cancelled after counterfeit medicines were allegedly relabelled as expensive Pfizer drugs. An SIT is probing the wider network. — [Source](https://www.freepressjournal.in/india/karnataka-spurious-drug-racket-government-halts-business-with-pfizer-cancels-licences-of-16-firms-over-counterfeit-medicine-manufacturing)
- 2026-09-21 — DECCANCHRONICLE.COM: **Spurious Drugs: Karnataka FDA Cancels 16 Drug Licences of Retailers, Wholesalers** — Officials said spurious drugs, machinery and printing materials valued at around Rs 5.05 crore were seized during the raid, with the inventory of seized materials estimated at Rs 4.91 crore — [Source](https://www.deccanchronicle.com/southern-states/karnataka/spurious-drugs-karnataka-fda-cancels-16-drug-licences-of-retailers-wholesalers-1989224)
- 2026-09-20 — DECCANCHRONICLE.COM: **Bengaluru: U.T. Khader Orders Action Against 24 Pharma Traders in Spurious Drugs Case** — Licences of 16 pharmaceutical distributors were cancelled, while those of eight others were suspended following the investigation. — [Source](https://www.deccanchronicle.com/southern-states/karnataka/bengaluru-ut-khader-orders-action-against-24-pharma-traders-in-spurious-drugs-case-1989127)
- 2026-09-20 — Mint: **Karnataka FDA cracks down on fake drug racket: 24 licences hit, ₹5 cr stock seized — what did it find during raid? | Today News** — Karnataka FDA has suspended eight drug licences and cancelled 16 due to counterfeit medicine distribution. A raid uncovered an illegal facility repacking drugs, with seized items valued at ₹5.05 crore. Authorities have warned of public health risks & urged consumers to buy from licensed pharmacies. — [Source](https://www.livemint.com/news/india/karnataka-fda-cracks-down-on-fake-drug-racket-24-licences-hit-rs-5-cr-stock-seized-what-did-it-find-during-raid-11789924262491.html)
- 2026-09-20 — The Hindu: **FSDA cancels 16 pharmacy licences, suspends 8, including Pfizer depot** — FDA cancels 16 pharmacy licenses, including Pfizer's, amid investigation into a major spurious drug repackaging operation in Bengaluru. — [Source](https://www.thehindu.com/news/cities/bangalore/fda-cancels-16-pharmacy-licences-suspends-8-including-pfizer-depot/article71488486.ece)
- 2026-09-09 — BUSINESSTODAY: **Novartis India shares zoom 20% to hit record high; Minipress deal fuels rally** — Novartis India, Novartis India shares, Minipress, Minipress XL, Pfizer India, Pfizer shares, pharma stocks, pharmaceutical stocks, trademark acquisition, Rs 1,250 crore deal, prazosin, hypertension, BPH, stock market, NSE, BSE — [Source](https://www.businesstoday.in/markets/stocks/story/novartis-india-shares-zoom-20-to-hit-record-high-minipress-deal-fuels-rally-554176-2026-09-09)
- 2026-09-08 — BUSINESSTODAY: **Pfizer shares hit 52-week low after Minipress XL discontinuation; Novartis zooms 13%** — Pfizer shares, Pfizer Ltd, Minipress XL, Novartis India, Novartis shares, Minipress, Minipres, Pfizer stock, Novartis stock, Rs 1,250 crore deal, Rs 131.38 crore, prazosin, hypertension, benign prostatic hyperplasia, BPH, pharmaceutical stocks, pharma shares, stock market news, 52-week low, 52-week high — [Source](https://www.businesstoday.in/markets/stocks/story/pfizer-shares-hit-52-week-low-after-minipress-xl-discontinuation-novartis-zooms-13-553906-2026-09-08)
- 2026-09-07 — DECCANCHRONICLE.COM: **Maharashtra: Novartis India buys Minipress brands from Pfizer for Rs 1250 crore** — Following the approval, Novartis India signed an asset purchase agreement and trademark assignment deeds: Reports — [Source](https://www.deccanchronicle.com/nation/maharashtra-novartis-india-buys-minipress-brands-from-pfizer-for-rs-1250-crore-1985582)
- 2026-09-07 — Economic Times: **360 One Group CEO Bhagat buys 1.3 lakh shares of Novartis India for Rs 22 cr** — Karan Bhagat acquired 1.3 lakh Novartis India shares for nearly Rs 22 crore. His firm Kyrush Investments sold an equal number of shares in the transaction. Novartis India also announced acquiring trademarks from Pfizer for Rs 1,250 crore. Earlier, Novartis AG agreed to sell its stake to a consortium. This deal excluded its innovative medicines business in the country. — [Source](https://economictimes.indiatimes.com/markets/stocks/news/360-one-group-ceo-bhagat-buys-1-3-lakh-shares-of-novartis-india-for-rs-22-cr/articleshow/133887525.cms)
- 2026-08-20 — MONEYCONTROL: **Quant MF raises Pfizer stake with Rs 131 cr purchase; Pari Washington buys over 2% in Amrutanjan Health Care** — Bulk Deals,Pfizer,Amrutanjan Health Care,Apollo Pipes,Welspun Investments and Commercials,Credent Connect N Care, — [Source](https://www.moneycontrol.com/news/business/markets/quant-mf-raises-pfizer-stake-with-rs-131-cr-purchase-pari-washington-buys-over-2-in-amrutanjan-health-care-14011816.html)
- 2026-08-20 — BUSINESS: **Volumes spurt at MMTC Ltd counter** — MMTC Ltd notched up volume of 373.46 lakh shares by 14:14 IST on NSE, a 29.12 fold spurt over two-week average daily volume of 12.82 lakh shares — [Source](https://www.business-standard.com/markets/capital-market-news/volumes-spurt-at-mmtc-ltd-counter-126082000669_1.html)
- 2026-08-17 — BUSINESS: **Global Markets Mixed Amid Geopolitical Tensions and Upcoming Economic Reports** — Stock futures show a varied start as investors monitor Middle East conflicts, retail earnings and upcoming Fed rate expectations. — [Source](https://www.business-standard.com/markets/capital-market-news/global-markets-mixed-amid-geopolitical-tensions-and-upcoming-economic-reports-126081700421_1.html)
- 2026-08-06 — Times of India: **Top stocks to buy today: Stock recommendations for August 6, 2026 - check list** — img border="0" hspace="10" align="left" style="margin-top:3px;margin-right:5px;" src="https://timesofindia.indiatimes.com/photo/132979582.cms" /Top stock market recommendations: Ambuja Cements, Asahi India Glass, and Pfizer - these stocks have been identified as the top buy calls for August 6, 2026 by Aakash K Hindocha, Vice President - Research, Nuvama Professional Clients Group/Nuvama Wealth Management. The expert has also shared outlook on Nifty50 and Bank Nifty: — [Source](https://timesofindia.indiatimes.com/business/india-business/top-stock-recommendations-for-august-06-2026-ambuja-cements-asahi-india-glass-pfizer-best-stocks-to-buy-today/articleshow/132979582.cms)
- 2026-07-29 — The Hindu: **Sensex today | Stock Market Live: Sensex jumps over 850 points, Nifty tops 24,240 as IT and consumer stocks lead rally** — Sensex, Nifty, Share Prices Live: Early stock market gains were led by IT, consumer and telecom stocks, even as global investors waited for the U.S. Federal Reserve's interest rate decision later in the day. — [Source](https://www.thehindubusinessline.com/markets/sensex-nifty50-today-stock-market-live-updates-29-july-2026/article71276758.ece)

## Business profile

**Strategic vision:** Develops and markets pharmaceutical products and healthcare solutions.

### Business segments
- **Pfizer Products India Pvt Ltd (PPIPL):** A wholly-owned subsidiary involved in importing, trading, marketing, and distribution of pharmaceutical products in Oncology, Rare Diseases, and Anti-infectives.
- **Pfizer Limited:** A publicly listed entity specializing in Vaccines, Hospitals, Internal Medicine, and Inflammation and Immunology.
- **Pfizer Healthcare India Private Limited (PHIPL):** Engaged in manufacturing and allied services, operating a manufacturing unit in Vizag that caters to the export market.

### Competitive strengths
- Global network of R&D centers
- State-of-the-art manufacturing facilities

## Related stocks

- [Acutaas Chemicals Limited (Healthcare)](https://faxioms.com/stocks/acutaas) — +0.30%
- [Blue Jet Healthcare Limited (Healthcare)](https://faxioms.com/stocks/bluejet) — -3.23%
- [Caplin Point Laboratories Limited (Healthcare)](https://faxioms.com/stocks/caplipoint) — -1.64%
- [Cohance Lifesciences Limited (Healthcare)](https://faxioms.com/stocks/cohance) — -3.56%
- [Concord Biotech Limited (Healthcare)](https://faxioms.com/stocks/concordbio) — -6.64%

## Freshness and sources

- Data as of: 2026-11-06
- Source: Faxioms public stock analysis API

Canonical: https://faxioms.com/stocks/pfizer
Markdown representation: https://faxioms.com/stocks/pfizer?render=md